Goodman Advisory Group LLC Invests $359,000 in Illumina, Inc. (NASDAQ:ILMN)

Goodman Advisory Group LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,522 shares of the life sciences company's stock, valued at approximately $359,000.

A number of other hedge funds have also recently modified their holdings of ILMN. Capital World Investors grew its position in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after acquiring an additional 14,481,232 shares during the period. Brown Advisory Inc. boosted its holdings in Illumina by 54,220.9% in the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock worth $255,586,000 after buying an additional 1,909,118 shares during the period. Norges Bank bought a new position in Illumina in the 4th quarter worth $228,714,000. Bessemer Group Inc. boosted its holdings in Illumina by 32,837.5% in the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock worth $180,152,000 after buying an additional 1,344,038 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in Illumina by 2,057.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock worth $73,174,000 after buying an additional 879,533 shares during the period. Institutional investors own 89.42% of the company's stock.

Illumina Price Performance

Shares of NASDAQ ILMN traded up $0.63 during mid-day trading on Friday, hitting $94.79. 3,837,289 shares of the company's stock traded hands, compared to its average volume of 2,142,698. The company's 50-day moving average is $82.69 and its two-hundred day moving average is $98.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.86 and a quick ratio of 1.48. The company has a market capitalization of $15.01 billion, a P/E ratio of -15.62, a PEG ratio of 1.86 and a beta of 1.32. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The business's revenue was down 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.98 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Ankur Dhingra acquired 6,100 shares of Illumina stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average cost of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at $2,022,616.26. This trade represents a 32.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 2.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ILMN has been the subject of several recent analyst reports. Morgan Stanley dropped their target price on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. JPMorgan Chase & Co. dropped their target price on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Canaccord Genuity Group upped their target price on shares of Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a report on Wednesday, June 11th. Finally, Citigroup decreased their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $127.39.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.